PDE4B and systemic lupus erythematosus: In fact, the PDE4B-specific small drug inhibitor NCS 613 has been shown to have anti-inflammatory properties in PBMCs from both healthy donors and SLE patients and is considered as a complementary strategy for the management of SLE23, 24.